CIPLA - IntraDay Trade Analysis with Live Signals
← Back to ListKey Parameters
⭐ IntraDay Trade Rating: 4.2
Show all parameters (20 more)
🧾 Trade Setup
Buy at 1365 ₹ with a stop-loss order set at 1340 ₹. Target profit level is 1400 ₹, reflecting immediate upward momentum driven by volume and recent financial results. Monitor closely – this trade has moderate risk due to the high P/E ratio and the significant variance in profits.
✅ Positive
The stock is experiencing a significant surge in volume, indicating strong buying interest following the record revenue announcement of ₹28,000 crore. Furthermore, the recent USFDA nod for Ventolin inhaler suggests continued positive momentum and potential upside today.
⚠️ Limitation
Despite the robust volume and positive news, the high P/E ratio (33.9) relative to the industry average (34.8) remains a concern, especially considering the -33.8% Qtr Profit Variance, potentially masking underlying growth challenges. The RSI of 48.2 also suggests some selling pressure is still present.
🏭 Industry
Pharma stocks are generally bullish due to ongoing demand for generic drugs and increasing healthcare spending. However, recent regulatory scrutiny within the sector remains a potential headwind, which today’s news seems to mitigate with the USFDA nod.